Breast Cancer

Latest News

Understanding the ‘Excitement’ Around ADCs for HR+/HER2– Breast Cancer
Understanding the ‘Excitement’ Around ADCs for HR+/HER2– Breast Cancer

March 13th 2024

With the progress made with ADCs, there is interest in moving these agents up in the treatment paradigm for HR-positive/HER2-negative breast cancer.

FDA Committee Supports Lumisight for Breast Cancer Detection During Surgery
FDA Committee Supports Lumisight for Breast Cancer Detection During Surgery

March 11th 2024

Making an Impact on Disparities in Radiotherapy for Breast Cancer
Making an Impact on Disparities in Radiotherapy for Breast Cancer

March 11th 2024

Olaparib Shows Manageable AEs in Early Breast Cancer
Olaparib Shows Manageable AEs in Early Breast Cancer

February 20th 2024

Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors

February 16th 2024

Video Series
Video Interviews
Podcasts
The Vitals
Oncology Nursing News
Are Hearing Tests Necessary For Adult Cancer Survivors?
Sarah Donahue Highlights Destiny-04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer
Key Advances in Cancer Survivorship Toxicity Management
Loyda Braithwaite Discusses Evolving Treatment Options in HR+ Breast Cancer
Latest CME Events & Activities

Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic

View More

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.